Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy

Hospices Civils de Lyon103 enrolled

Overview

The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral treatment

Presence of anti-E1E2 antibodies was previously associated with spontaneous cure of hepatitis C virus (HCV). The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in HCV-infected patients receiving direct-acting antiviral treatment

Study Type

OBSERVATIONAL

Enrollment

103

Conditions

Chronic Hepatitis c

Interventions

Direct-acting antiviral therapyDRUG

HCV patients received direct-acting antiviral treatment for 12 or 24 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years of age or older * HCV patients treated with direct-acting antiviral treatment * Patients with a prior treatment blood sample * Patients with sustained virological response or virological relapse Exclusion Criteria: * HIV or hepatitis B virus (HBV) coinfection

Locations (1)

Croix-Rousse Hospital, Hospices Civils de Lyon

Lyon, France

Outcomes

Primary Outcomes

Proportion of patients with positive anti-E1E2 antibody level at treatment initiation

Anti-E1E2 antibody levels were determined using optical densities obtained after dilution of patients' serum samples at 1/250 and 1/500. Samples with anti-E1E2 levels above 950 (OD value× 1000) were considered positive

Time frame: Baseline (treatment initiation day)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.